The relevance assay on the IC50 of the HNSCC cell lines treated with anti-tumor drugs in GDSC database disclosed that the GSVA scores of CXCL9, CXCL10, CXCL11, and CCL5 were negatively correlated to ERK1-MARK (Figures 7B–H) and RAS pathway (Figures 7I,J) targeted by anti-HNSCC drugs, implicating that the susceptibility of the immune hot subtype of HNSCC to the drug originated from the influence on ERK1-MARK and RAS pathway. The gene discussed is CCL5; the disease is head and neck squamous cell carcinoma.